Samsung Biologics expands US presence with acquisition of Human Genome Sciences Facility in Maryland

USA—Samsung Biologics has signed a definitive agreement through its subsidiary, Samsung Biologics America, to acquire Human Genome Sciences from GSK.

The acquisition, valued at USD 280 million, marks a significant step in the company’s plan to expand its manufacturing capabilities and establish a stronger presence in the United States.

This deal gives Samsung Biologics its first manufacturing site in the US and reinforces its long-term commitment to serving the North American biopharmaceutical market.

The acquired facility is located in Rockville, Maryland—a major US bio-cluster known for its concentration of biotechnology and life sciences companies.

The site includes two current good manufacturing practice (cGMP) plants with a combined drug substance capacity of 60,000 litres.

The Rockville facility is designed to support both clinical and commercial manufacturing needs, handling varying batch sizes for a range of biologics.

Samsung Biologics plans to maintain the production of existing products while investing in the site’s expansion and modernization.

The company aims to upgrade the facility’s technologies to enhance capacity, efficiency, and the overall reliability of the US biologics supply chain.

Under the terms of the agreement, Samsung Biologics will retain more than 500 employees at the Rockville site to ensure operational continuity and a smooth integration process.

The transaction is expected to close by the end of the first quarter of 2026, subject to customary closing conditions and regulatory approvals.

Integrating the Rockville facility into Samsung Biologics’ global network will allow the company to offer multi-site and flexible manufacturing options to its clients across Korea and the United States.

This expanded network aims to provide biopharmaceutical companies with increased production flexibility and secure access to advanced therapeutics for American patients.

Currently, Samsung Biologics operates five plants with a total capacity of 785,000 litres, producing a broad portfolio that includes messenger ribonucleic acid (mRNA), monoclonal antibodies, antibody-drug conjugates (ADCs), next-generation therapies, and organoid-based services.

The company has also completed the development of Bio Campus I and II and acquired land for its upcoming Bio Campus III, which will focus on manufacturing innovation and new research programs.

Commenting on the acquisition, John Rim, president and CEO of Samsung Biologics, described the move as a landmark moment for the company.

He stated that the investment underscores Samsung Biologics’ commitment to advancing global healthcare and strengthening US-based manufacturing capabilities.

Rim added that the deal will enhance collaboration with federal, state, and local partners while ensuring a dependable supply of life-saving therapeutics.

Earlier in 2025, Samsung Biologics expanded its partnership with LigaChem Biosciences to advance the development and manufacturing of antibody-drug conjugates, reflecting its growing focus on next-generation biopharmaceutical solutions.